Dyne’s DMD Therapy Wins Priority Review

Company Dyne Therapeutics Event Type Regulatory Milestone (FDA BLA Acceptance / Priority Review) Modality Antibody-Oligonucleotide Conjugate (FORCE Platform, Exon-Skipping) Asset Zeleciment rostudirsen (z-rostudirsen / DYNE-251) Target Transferrin Receptor 1 (delivery) / DMD Exon 51 Disease Area Duchenne Muscular Dystrophy Summary The FDA accepted Dyne Therapeutics’…